phrykt

Vera Therapeutics, Inc. (VERA): who owns it and who trades it

As of Nov 16, 2026, VERA insiders reported 24 open-market sales worth $8.6M and 1 purchase worth $250K in the last 12 months, with 66% of the sale value made under pre-set 10b5-1 plans. The largest seller was Marshall Fordyce (CEO), with $6.4M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Vera Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns VERA

219 funds and institutions reported VERA shares worth $3.4B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 8.0%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.8.0%
Avoro Capital Advisors LLC8.0%
State Street Corp5.8%
T. Rowe Price Associates5.6%
Deep Track Capital, LP5.6%
Deerfield Management Company, L.P.5.5%
Kynam Capital Management, LP4.0%
Morgan Stanley3.9%
Sofinnova Investments, Inc.3.9%
FMR LLC (Fidelity)3.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.5.75M8.01%$247M+13%
Avoro Capital Advisors LLC5.72M7.97%$246M-3%
State Street Corp4.15M5.78%$178M+23%
T. Rowe Price Associates4.01M5.59%$172M-12%
Deep Track Capital, LP4.00M5.57%$172M-3%
Deerfield Management Company, L.P.3.92M5.46%$168M+5%
Kynam Capital Management, LP2.89M4.03%$124M-15%
Morgan Stanley2.80M3.90%$120M+659%
Sofinnova Investments, Inc.2.79M3.89%$120MNo change
FMR LLC (Fidelity)2.77M3.86%$119M+4%
Vanguard Capital Management LLC2.76M3.84%$118M+3%
Eversept Partners, LP2.21M3.08%$94.9M+2%
Logos Global Management LP2.20M3.06%$94.4M–
California State Teachers Retirement System2.07M2.89%$48.4M+4072%
Integral Health Asset Management, LLC1.75M2.44%$75.1M+9%
Bellevue Group AG1.71M2.38%$73.4MNo change
Geode Capital Management, LLC1.69M2.36%$72.6M+8%
Alliancebernstein L.P.1.59M2.22%$64M+21%
Goldman Sachs Group Inc1.38M1.92%$59.3M+22%
Frontier Capital Management Co LLC1.30M1.80%$55.6M+135%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, VERA insiders reported $250K of open-market purchases and $8.6M of sales. 66% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$250K
1 trades, 1 people
Sales, 12 months
$8.6M
24 trades, 8 people
Sales under a 10b5-1 plan
66%
Share of sale value
Latest trade
Sep 15, 2026
Filed Sep 17, 2026

Purchases and sales by month

$2M$2MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 15, 2026Marshall FordyceCEOSale plan18,500$37.00$684KForm 4
Sep 2, 2026Marshall FordyceCEOSale plan18,500$35.12$650KForm 4
Jul 7, 2026Marshall FordyceCEOSale plan1,000$40.78$40.8KForm 4
Jul 7, 2026Marshall FordyceCEOSale plan2,200$43.59$95.9KForm 4
Jul 7, 2026Marshall FordyceCEOSale plan10,500$42.86$450KForm 4
Jul 7, 2026Marshall FordyceCEOSale plan32,550$42.07$1.4MForm 4
Jun 23, 2026Marshall FordyceCEOSale plan18,412$37.93$698KForm 4
Jun 23, 2026Marshall FordyceCEOSale plan88$38.43$3.4KForm 4
May 12, 2026Marshall FordyceCEOSale plan14,219$36.64$521KForm 4
May 12, 2026Marshall FordyceCEOSale plan4,281$37.09$159KForm 4
Apr 14, 2026Marshall FordyceCEOSale plan14,130$43.66$617KForm 4
Apr 14, 2026Marshall FordyceCEOSale plan900$45.51$41KForm 4
Apr 14, 2026Marshall FordyceCEOSale plan7,921$44.58$353KForm 4
Feb 23, 2026Robert BrennerChief Medical OfficerSale2,151$41.98$90.3KForm 4
Feb 23, 2026Joseph R YoungVice presidentSale3,117$41.98$131KForm 4
Feb 23, 2026Sean GrantCFOSale4,949$41.98$208KForm 4
Feb 23, 2026Marshall FordyceCEOSale16,925$41.98$711KForm 4
Feb 23, 2026David Lee JohnsonChief Operating OfficerSale2,579$41.98$108KForm 4
Feb 23, 2026William D. TurnerChief Regulatory OfficerSale2,187$41.98$91.8KForm 4
Feb 23, 2026Laurence Matthew SkeltonChief Commercial OfficerSale1,582$41.98$66.4KForm 4
Dec 15, 2025William D. TurnerChief Regulatory OfficerSale10,000$50.08$501KForm 4
Dec 11, 2025Patrick G EnrightDirectorPurchase5,882$42.50$250KForm 4
Dec 8, 2025William D. TurnerChief Regulatory OfficerSale10,000$45.31$453KForm 4
Dec 3, 2025William D. TurnerChief Regulatory OfficerSale10,000$40.00$400KForm 4
Nov 21, 2025Jason S CarterChief Legal OfficerSale3,864$27.82$107KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Marshall FordycePRESIDENT AND CEO, Director–$6.4MSep 15, 2026
William D. TurnerChief Regulatory Officer–$1.4MFeb 23, 2026
Patrick G EnrightDirector$250K–Dec 11, 2025
Sean GrantCHIEF FINANCIAL OFFICER–$208KFeb 23, 2026
Joseph R YoungSVP, FINANCE, CHIEF ACCT OFFCR–$131KFeb 23, 2026
David Lee JohnsonChief Operating Officer–$108KFeb 23, 2026
Jason S CarterChief Legal Officer–$107KNov 21, 2025
Robert BrennerChief Medical Officer–$90.3KFeb 23, 2026
Laurence Matthew SkeltonChief Commercial Officer–$66.4KFeb 23, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

VERA short interest

High short interest. 16.8% of VERA shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 20%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 12.14M VERA shares were sold short, 16.8% of the shares outstanding, down 10.6% from the report before. At the average daily volume of 1.43M shares, buying them all back would take about 8.5 trading days (days to cover).

Shares short, % of all shares

16.8%May 15Oct 3029.6%

Days to cover

8.5May 15Oct 3012.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202612.14M16.79%-11%1.43M8.5
Oct 15, 202613.59M18.85%-21%1.90M7.2
Sep 30, 202617.24M23.92%+1%2.21M7.8
Sep 15, 202617.04M23.64%-14%2.76M6.2
Aug 31, 202619.87M27.58%+18%1.84M10.8
Aug 14, 202616.81M23.33%+10%2.42M7.0
Jul 31, 202615.28M21.21%+1%1.62M9.4
Jul 15, 202615.08M21.01%+12%3.02M5.0
Jun 30, 202613.52M18.84%+14%2.30M5.9
Jun 15, 202611.84M16.49%+9%1.14M10.4
May 29, 202610.83M15.09%+7%969,22911.2
May 15, 202610.08M14.04%+7%1.01M10.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Vera Therapeutics company events

Vera Therapeutics filed 13 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Sep 15, 2026AnnouncementAs noted in Item 7.01, on September 15, 2026, the Company announced that TRUTAKNA met all prespecified endpoints of the final efficacy analysis of the ORIGIN 3 trial in adults with primary IgAN at risk for disease progression. Filing
  3. Aug 10, 2026ResultsReleased financial results. Filing
  4. Jul 9, 2026LeadershipVera Therapeutics, Inc. announced that William Turner will no longer serve as the Company’s Chief Regulatory Officer and will transition to the role of Special Advisor for Regulatory Affairs, effective as of August 3, 2026. Filing
  5. Jul 7, 2026AnnouncementVera Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted TRUTAKNA™ (atacicept-vymj) accelerated approval to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression. Filing
  6. Jun 2, 2026AnnouncementVera Therapeutics, Inc. issued a press release announcing that the Company has aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan to support the potential full approval of atacicept in adults with IgA Nephropathy. Filing
  7. May 26, 2026VoteReported shareholder vote results. Filing
  8. May 7, 2026ResultsReleased financial results. Filing
  9. Mar 9, 2026LeadershipThe board of directors of Vera Therapeutics, Inc. appointed Christopher Hite to the Board, effective immediately. Filing
  10. Feb 26, 2026ResultsReleased financial results. Filing
  11. Dec 18, 2025LeadershipVera Therapeutics, Inc. announced that Jason Carter will no longer serve as the Company’s Chief Legal Officer, effective as of December 24, 2025. Filing
  12. Dec 10, 2025AnnouncementVera Therapeutics, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein, relating to the issuance and sale in a public offering of… Filing
  13. Nov 26, 2025LeadershipThe board of directors of Vera Therapeutics, Inc. appointed James R. Meyers to the Board, effective immediately. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Vera Therapeutics financials

Famous investors that hold VERA

2 of the 50 well-known investors we track reported holding VERA in their latest 13F filing. The largest position is Israel Englander's, worth $27.1M.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026838,290$27.1M0.0%+201%
Paul Tudor Jones · Tudor Investment CorpQ3 202624,775$800K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named VERA in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Avoro Capital Advisors LLC13G/A7.8%
Nov 16, 2026Deep Track Capital, LP13G/A9.7%
Nov 16, 2026T. Rowe Price Associates, Inc.13G/A3.8%
Nov 16, 2026T. Rowe Price Associates, Inc.13G/A3.8%
Nov 16, 2026Avoro Capital Advisors LLC13G/A7.8%
Nov 16, 2026Deep Track Capital, LP13G/A9.7%
Nov 10, 2026STATE STREET CORPORATION13G4.6%
Nov 10, 2026STATE STREET CORPORATION13G4.6%

Questions about Vera Therapeutics, Inc. (VERA) stock

Who owns the most VERA stock?

The largest reported owner of Vera Therapeutics, Inc. (VERA) is BlackRock, Inc., with 8.0% of the company. In total, 219 funds and institutions reported holding VERA at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are VERA insiders buying or selling?

In the last 12 months, VERA insiders reported 1 open-market purchase worth $250K and 24 sales worth $8.6M. The latest trade was on Sep 15, 2026. See every trade.

What is the short interest in VERA?

As of Oct 30, 2026, 12.14M VERA shares were sold short, 16.8% of the shares outstanding, down 10.6% from the report before. At the average daily volume of 1.43M shares, buying them all back would take about 8.5 trading days (days to cover). See the history.

Which famous investors hold VERA?

2 of the 50 well-known investors we track reported VERA in their latest 13F filing, including Israel Englander, Paul Tudor Jones. The largest position is worth $27.1M. See all holders.

Executive pay

Vera Therapeutics's chief executive was paid a total of $7M for the year ended Dec 31, 2025, up 24% from $5.6M the year before. In the last 12 months, Vera Therapeutics's executives and directors bought $250K of stock on the open market and sold $8.6M.

Chief executive, total pay$7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$9.1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.6MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.